Back to top
more

CoDiagnostics (CODX)

(Delayed Data from NSDQ)

$0.26 USD

0.26
649,710

+0.01 (3.42%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $0.26 0.00 (1.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Zacks Equity Research

COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.

Zacks Equity Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CoDiagnostics (CODX) delivered earnings and revenue surprises of 27.27% and 86.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Concentra Group (CON) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Concentra (CON) delivered earnings and revenue surprises of 3.23% and 0.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy

by Zacks Equity Research

CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

CoDiagnostics (CODX) delivered earnings and revenue surprises of -5.88% and 60.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of -8.70% and 20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Beauty Health Company (SKIN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beauty Health (SKIN) delivered earnings and revenue surprises of 20% and 8.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organon (OGN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 4.65% and 1.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CoDiagnostics (CODX) delivered earnings and revenue surprises of 3.03% and 60.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sotera Health Company (SHC) Q3 Earnings Lag Estimates

by Zacks Equity Research

Sotera Health (SHC) delivered earnings and revenue surprises of -10.53% and 2.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of -12.99% and 5.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alignment HealthCare Partners With Intermountain Health in Nevada

by Zacks Equity Research

ALHC partners with Intermountain Health to enhance access to high-quality care for Medicare members in Clark and Washoe counties, starting Jan 2025.

Zacks Equity Research

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

by Zacks Equity Research

Here is how Context Therapeutics Inc. (CNTX) and Co-Diagnostics, Inc. (CODX) have performed compared to their sector so far this year.

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CoDiagnostics (CODX) delivered earnings and revenue surprises of 26.47% and 564.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 57.69% and 19.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Icon PLC (ICLR) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 1.63% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elevance Health (ELV) Beats Q1 Earnings Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Icon PLC (ICLR) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sharecare, Inc. (SHCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sharecare, Inc. (SHCR) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ModivCare (MODV) Misses Q1 Earnings Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of -4.05% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?